We are 3,5-Dibromo-4-hydroxybenzaldehyde CAS:2973-77-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests
Related News: Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.96-32-2 Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs.1,2-BIS(DICHLOROMETHYLSILYL)ETHANE The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%.4-Amino-2-bromopyridine Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added “The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.The technology supports breakthroughs in medical research and is widely used by major global pharmaceutical companies to advance drug discovery & development and provide data to support regulatory submissions.
Product Name | |
---|---|
Sodium Azide Cas:26628-22-8 | View Details |
1,3-Dibromo-5-fluorobenzene | View Details |
O-phosphoethanolamine Cas:1071-23-4 | View Details |